Becampanel

Becampanel

Clinical data
ATC code	None
Identifiers
IUPAC name ({[(2,3-Dihydroxy-7-nitro-5-quinoxalinyl)methyl]amino}methyl)phosphonic acid
CAS Number	188696-80-2
PubChem (CID)	5491960
ChemSpider	4590791
Chemical and physical data
Formula	C10H11N4O7P
Molar mass	330.191 g/mol
3D model (Jmol)	Interactive image
SMILES c1c(cc2c(c1CNCP(=O)(O)O)[nH]c(=O)c(=O)[nH]2)[N+](=O)[O-]
InChI InChI=1S/C10H11N4O7P/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11H,3-4H2,(H,12,15)(H,13,16)(H2,19,20,21) Key:ABFMMCZFKUIJGQ-UHFFFAOYSA-N

Becampanel (INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC₅₀ = 11 nM).^[1][2][3][4] It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.^[1][2][3][5]

References

1. John B. Taylor; D. J. Triggle (2007). Comprehensive medicinal chemistry II. Elsevier. p. 290. ISBN 978-0-08-044513-7.
2. Kwan P, Brodie MJ (September 2007). "Emerging drugs for epilepsy". Expert Opin Emerg Drugs. 12 (3): 407–22. doi:10.1517/14728214.12.3.407. PMID 17874969.
3. Citraro R, Aiello R, Franco V, De Sarro G, Russo E (March 2014). "Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy". Expert Opin. Ther. Targets. 18 (3): 319–34. doi:10.1517/14728222.2014.874416. PMID 24387310.
4. World Health Organization (1988). International Nonproprietary Names (INN) for Pharmaceutical Substances. W.H.O.
5. Pathan SA, Jain GK, Akhter S, Vohora D, Ahmad FJ, Khar RK (September 2010). "Insights into the novel three 'D's of epilepsy treatment: drugs, delivery systems and devices". Drug Discov. Today. 15 (17-18): 717–32. doi:10.1016/j.drudis.2010.06.014. PMID 20603226.